Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday formalized multiple commercial Group Purchasing Organization (GPO) agreements for Rezenopy (naloxone HCl) Nasal Spray 10 mg.
Rezenopy, an opioid antagonist, received FDA approval in April 2024 for the emergency treatment of known or suspected opioid overdose.
Scienture secured exclusive U.S. commercialization rights to Rezenopy from Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025.
Expanded Institutional Footprint For Scienture
The agreement provides access to over 5000 healthcare institutions, including hospitals, clinics, and nursing homes, representing potential penetration into roughly 60% of the U.S. institutional market.
The deal also establishes a broad footprint across first responders, EMS providers, and rehabilitation centers.
“These GPO agreements represent a significant step forward in the commercial expansion of Rezenopy,” commented Narasimhan Mani, President and co-CEO of Scienture
Shankar Hariharan, Executive Chairman and co-CEO of Scienture, added, “Institutional procurement channels are a key driver of growth for emergency overdose treatments.”
“We expect broader availability through these institutional channels to drive adoption and strengthen our growth trajectory as we scale our commercial operations,” said Hariharan.
US Naloxone Market Totals $141 Million
“With the U.S. naloxone market representing approximately $141 million in annual sales and 9.4 million prescription units, we believe Rezenopy, the highest-dose FDA-approved naloxone nasal spray, is well-positioned to drive broader adoption and capture market share as we continue executing our commercialization strategy,” Mani said.
IQVIA data (MAT January 2026) indicates total annual sales of $141 million, and unit volume of 9.4 million (eaches) for naloxone in the U.S. market.
Patent Win
In January, Summit Biosciences secured a U.S. patent covering Rezenopy, with an expiry date of February 5, 2041.
In December 2025, Scienture and Blink Rx LLC announced a new collaboration to expand access to a novel hypertension therapy via an oral suspension medication.
The companies revealed that the liquid drug formulation, branded Arbli, will become available on the BlinkRx platform in the first quarter of 2026.
SCNX Price Action: Scienture stock is up 1.42% at $0.394 during the premarket session at the last check on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments